• Home
  • News
  • Fortune 500
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
    • Great Place to Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • FORTUNE 500
    • FORTUNE 500
    • FORTUNE SEA 500
    • Fortune 500 Europe
    • Fortune Global 500
    • Fortune China 500
    • Great Place to Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Banking
    • Investing
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics

Sy Mukherjee

Sy Mukherjee is a former health care reporter for Fortune.

    Page 22 of 100

  • Nestle Aimmune Peanut Allergy DrugNewsletters

    Nestlé invests another $200 million in Aimmune’s peanut allergy drug

    By Sy Mukherjee
  • Gates Foundation Coronavirus DonationHealth

    The Gates Foundation is pledging up to $100 million for the fight against coronavirus

    By Sy Mukherjee
  • On Tuesday Venture capital giant Andreessen Horowitz announced a third iteration of its biopharmaceutical and digital health fund.Newsletters

    What Andreessen’s ‘Bio Fund III’ means for healthcare

    By Sy Mukherjee
  • A South African clinical trial of a vaccine for HIV has been nixed after being found ineffective, a major blow to public health efforts.Newsletters

    A vaccine that looked promising for HIV doesn’t work

    By Sy Mukherjee
  • Coronavirus vaccine developmentHealth

    The first coronavirus drug candidate is set for testing in China

    By Sy Mukherjee
  • At the promotional bonanza called Radio Row, former NFL athlete Solomon Wilcots promoted Flexion’s long-lasting knee pain drug Zilretta.Health

    For what ails Super Bowl athletes? Former NFL player talks up a new long-lasting knee treatment

    By Sy Mukherjee
  • Vertex Pharmaceuticals Earnings 2019Newsletters

    Vertex CEO takes an earnings victory lap right before he exits

    By Sy Mukherjee
  • Eli Lilly Earnings Diabetes SalesNewsletters

    Eli Lilly smashed Wall Street projections thanks to its diabetes drugs

    By Sy Mukherjee
  • Wuhan coronavirus transmissionHealth

    How the Wuhan coronavirus spreads and what’s being done about it

    By Sy Mukherjee
  • Novartis Zolgensma Gene Therapy SalesNewsletters

    Why a drug that costs $2.1 million per dose is on a sales streak

    By Sy Mukherjee
  • Bloomberg Drug PricesNewsletters

    One drug, one patent?

    By Sy Mukherjee
  • Michael Bloomberg Drug Pricing PatentsHealth

    Michael Bloomberg’s radical plan to cut prescription drug costs

    By Sy Mukherjee
  • Kobe Bryant Death Science of GriefNewsletters

    Kobe Bryant and the science of grief

    By Sy Mukherjee
  • China Coronavirus VaccineNewsletters

    The hunt for a coronavirus vaccine begins

    By Sy Mukherjee
  • Telehealth Ro Pfizer ViagraHealth

    Telehealth startup Ro partners with Pfizer to give its ED business a boost

    By Sy Mukherjee
    Rankings
    • 100 Best Companies
    • Fortune 500
    • Global 500
    • Fortune 500 Europe
    • Most Powerful Women
    • Future 50
    • World’s Most Admired Companies
    • See All Rankings
    Sections
    • Finance
    • Leadership
    • Success
    • Tech
    • Asia
    • Europe
    • Environment
    • Fortune Crypto
    • Health
    • Retail
    • Lifestyle
    • Politics
    • Newsletters
    • Magazine
    • Features
    • Commentary
    • MPW
    • CEO Initiative
    • Conferences
    • Personal Finance
    • Education
    Customer Support
    • Frequently Asked Questions
    • Customer Service Portal
    • Privacy Policy
    • Terms of Use
    • Single Issues for Purchase
    • International Print
    Commercial Services
    • Advertising
    • Fortune Brand Studio
    • Fortune Analytics
    • Fortune Conferences
    • Business Development
    About Us
    • About Us
    • Editorial Calendar
    • Press Center
    • Work at Fortune
    • Diversity and Inclusion
    • Terms and Conditions
    • Site Map

    © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.